Alrestatin is primarily used in research related to diabetic complications, particularly in studies focusing on the prevention of sorbitol accumulation in tissues. It acts as an aldose reductase inhibitor, which helps reduce the levels of sorbitol formed via the polyol pathway. Excessive sorbitol buildup in the lens, nerves, and retina under hyperglycemic conditions contributes to cataract formation, neuropathy, and retinopathy. By inhibiting this pathway, Alrestatin has been investigated for its potential to delay or prevent such complications in diabetic patients. Although it has not been widely adopted for clinical use, it remains a valuable tool in understanding the role of aldose reductase in metabolic diseases and in the development of more effective inhibitors.